Abstract
Merlin, the protein product of NF2 gene, is one of the most versatile tumor suppressors capable of integrating different mechanisms that regulate cell proliferation, motility, survival and signaling pathways underlying and governing those mechanisms. Merlin is considered a member of the band 4.1 families of cytoskeleton-associated proteins also called ERM family and acts as tumor suppressor. The main cause for transformation of Schwann cells into schwannomas is credited to the inactivation of the neurofibromin 2 (NF2) gene and the consecutive loss of its protein merlin. Recent scientific advances improved our understanding of pathogenic mechanisms involving NF2 gene. The present review brings genetic properties of NF2 gene, molecular characteristics of merlin, summarizes mutational spectra and explains merlin’s multifunctional roles regarding its involvement in neurofibromatosis associated tumorigenesis.
Similar content being viewed by others
References
Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515–521
Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K et al (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791–800
Gusella JF, Ramesh V, MacCollin M, Jacoby LB (1999) Merlin: the neurofibromatosis 2 tumor suppressor. Biochim Biophys Acta 1423:M29–M36
Stamenkovic I, Yu Q (2010) Merlin, a “magic” linker between the extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 11:471–484
Sughrue MI, Yeung AH, Rutkowski MJ, Cheung SW, Parsa AT (2011) Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. J Neurosurg 114:359–366
Ammoun S, Hanemann CO (2011) Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol 7:3992–3999
Zhou L, Hanemann CO (2012) Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett 586:1403–1408
Entrez, the life science search engine (http://www.ncbi.nlm.nih.gov/sites/gquery)
McClatchey AI (2007) Neurofibromatosis. Annu Rev Pathol Mech Dis 2:191–216
Shimizu T, Seto A, Maita N, Hamada K, Tsukita S, Hakoshima T (2002) Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Biol Chem 277:10332–10336
Hanemann CO (2008) Magic but treatable? Tumours due to loss of Merlin. Brain 131:606–615
UniProtKB/Swiss-Prot (http://www.uniprot.org/uniprot/P35240#section_comments)
Laulajainen M, Melikova M, Muranen T, Carpen O, Gronholm M (2012) Dictinct overlapping sequences at the carboxy-terminus of merlin regulate its tumor suppressor and morphogenic activity. J Cell Mol Med 16:2161–2175
Carroll SL (2012) Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol 123:321–348
Alfthan K, Heiska L, Grönholm M, Renkema GH, Carpén O (2004) Cyclic AMP-demendent protein kinase phosphorylates merlin at serine 518 independently of p21 activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem 279:18559–18566
McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T (1997) The NF2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev 11:1253–1265
Hanemann CO, Evans DG (2006) News on the genetics, epidemiology, medical care and translational research of Schwannomas. J Neurol 253:1533–1541
Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G (2000) Conditional biallelic NF2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14:1617–1630
Lutchman M, Rouleau GA (1995) The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res 55:2270–2274
Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H (1994) An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 269:23387–23390
Scoles DR (2008) The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta 1785:32–54
Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P (2001) The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15:968–980
Okada T, Lopez-Lago M, Giancotti FG (2005) Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 171:361–371
Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI (2003) NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17:1090–1100
Li W, Cooper J, Karajannis MA, Giancotti FG (2012) Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep 13:204–215
Kim H, Kwak NJ, Lee JY, Choi BH, Lim Y, Ko YJ, Kim YH, Huh PW, Lee KH, Rha HK, Wang YP (2004) Merlin neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 279:7812–7818
Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E, Biggerstaff J, Iacovelli J (2002) Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 31:354–362
Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P (2007) Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 67:520–527
Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D, Hung G (2003) Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23:1493–1500
Okada M, Wang Y, Jang SW, Tang X, Neri LM, Ye K (2009) Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res 69:4043–4051
Bosco EE, Nakai Y, Hennigan RF, Ratner N, Zheng Y (2010) NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene 29:2540–2549
Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA, Hanemann CO (2011) Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-Catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia 13:1101–1112
Lau YKI, Murray LB, Houshmandi SS, Nu Y, Gutmann DH, Yu Q (2008) Merlin is a potent inhibitor of glioma growth. Cancer Res 68:5733–5742
Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841–846
Jacoby LB, MacCollin M, Barone R, Ramesh V, Gusella JF (1996) Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosom Cancer 17:45–55
Irving RM, Harada T, Moffat DA, Hardy DG, Whittaker JL, Xuereb JH, Maher ER (1997) Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma. Am J Otol 18:754–760
The Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=NF2)
Antinheimo J, Sallinen SL, Sallinen P, Haapasalo H, Helin H, Horelli-Kuitunen N, Wessman M, Sainio M, Jääskeläinen J, Carpén O (2000) Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated Schwannomas studied by comparative genomic hybridization (CGH). Acta Neurochir 142:1099–1105
Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, Nunes FP (2007) Mutational spectrum of NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat 28:1–12
Welling DB, Akhmametyeva EM, Daniels RL, Lasak JM, Zhu L, Miles-Markley BA, Chang LS (2000) Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Otolaryngology 123:413–418
Gutmann DH, Geist RT, Xu H, Kim JS, Saporito-Irwin S (1998) Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 7:335–345
Fong B, Barkhoudarian G, Pezeshkian P, Parsa AT, Gopen Q, Yang I (2011) The molecular biology and novel treatments of vestibular schwannomas. J Neurosurg 115:906–914
Scheithauer BW, Louis DN, Hunter S, Woodruff JM, Antonescu CR (2007) Tumours of the cranial and paraspinal nerves. Schwannoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon, pp 152–155
Ghosh A, Talwar OP, Pradhan SV (2010) Tumour and tumour-like conditions of peripheral nerve origin: ten years’ experience. Kathmandu Univ Med J 29:97–101
Celis-Aguilar E, Lassaletta L, Torres-Martin M, Rodrigues FY, Nistal M, Castresana JS, Gavilan J, Ray JA (2012) The molecular biology of vestibular schwannomas and its association with hearing loss: a review. Genet Res Int. Article ID 856157:10. doi:10.1155/2012/856157
Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER (1993) Molecular genetic analysis of the mechanism of tumorigenesis in acoustic neuroma. Arch Otolaryngol Head Neck Surg 119:1222–1228
Hitotsumatsu T, Iwaki T, Kitamoto T, Mizoguchi M, Suzuki SO, Hamada Y, Fukui M, Tateishi J (1997) Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol 93:225–232
Lee DJ, Maseyesva B, Westra W, Long D, Niparko JK, Califano J (2006) Microsatellite analysis of recurrent vestibular Schwannoma (acoustic neuroma) following stereotactic radiosurgery. Otol Neurotol 27:213–219
Pećina-Šlaus N, Zeljko M, Pećina HI, Nikuševa Martić T, Bačić N, Tomas D, Hrašćan R (2012) Frequency of loss of heterozygosity of the NF2 gene in schwannomas from Croatian patients. Croat Med J 53:321–327
Bian LG, Sun QF, Tirakotai W, Zhao WG, Shen JK, Luo QZ, Bertalanffy H (2005) Loss of heterozygosity on chromosome 22 in sporadic schwannoma and its relation to the proliferation of tumor cells. Chin Med J (Engl) 118:1517–1524
Hadfield KD, Smith MJ, Urquhart JE, Wallace AJ, Bowers NL, King AT, Rutherford SA, Trump D, Newman WG, Evans DG (2010) Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29:6216–6221
Mantripragada KK, Buckley PG, Benetkiewicz M, De Bustos C, Hirvela C, Jarbo C, Bruder CE, Wensman H, Mathiesen T, Nyberg G, Papi L, Collins VP, Ichimura K, Evans G, Dumanski JP (2003) High-resolution profiling of an 11 Mb segment of human chromosome 22 in sporadic schwannoma using array-CGH. Int J Oncol 22:615–622
Warren C, James LA, Ramsden RT, Wallace A, Baser ME, Varley JM, Evans DG (2003) Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridization. J Med Genet 40:802–806
Koutsimpelas D, Felmeden U, Mann WJ, Brieger J (2011) Analysis of cytogenetic aberrations in sporadic vestibular schwannoma by comparative genomic hybridization. J Neurooncol 103:437–443
Aarhus M, Bruland O, Sætran HA, Mork SJ, Lund-Johansen M, Knappskog PM (2010) Global gene expression profiling and tissue microarray reveal novel candidate genes and down-regulation of the tumor suppressor gene CAV1 in sporadic vestibular schwannomas. Neurosurgery 67:998–1019
Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T (1999) Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59:5995–5998
Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekane dit Deprez R, Zwarthoff E (2001) NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367–372
Fuller CE, Perry A (2005) Molecular diagnostics in central nervous system tumors. Adv Anat Pathol 12:180–194
Claus EB, Bondy ML, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57:1088–1094
Riemenschneider MJ, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045–1054
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
Lee JY, Finkelstein S, Hamilton RL, Rekha R, King JT Jr, Omalu B (2004) Loss of heterozygosity analysis of benign, atypical, and anaplastic meningiomas. Neurosurgery 55:1163–1173
Ragel BT, Jensen RL (2005) Molecular genetics of meningiomas. Neurosurg Focus 119:E9
Barnholtz-Sloan JS, Kruchko C (2007) Meningiomas: causes and risk factors. Neurosurg Focus 23:E2
Simon M, Boström JP, Hartmann C (2007) Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 60:787–798
Pećina-Šlaus N, Nikuševa Martić T, Deak AJ, Zeljko M, Hrašćan R (2010) Genetic and protein changes of E-cadherin in meningiomas. J Cancer Res Clin Oncol 136:695–702
Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P (2007) Germline mutation of INI1/SMARCB1 in familial Schwannomatosis. Am J Hum Genet 80:805–810
Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M (2013) Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria. Am J Med Genet 161:405–416
Acknowledgments
This work was supported by grant 108-1081870-1905 from Ministry of Science Sports and Education, Republic of Croatia.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pećina-Šlaus, N. Merlin, the NF2 Gene Product. Pathol. Oncol. Res. 19, 365–373 (2013). https://doi.org/10.1007/s12253-013-9644-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-013-9644-y